15d • General discussion
GLP-1 RA Categories of Contraindications: Brief
When considering semaglutide (GLP-1 agonist), tirzepatide (GLP-1/GIP dual agonist), and retatrutide (GLP-1/GIP/glucagon triple agonist), contraindications can be grouped into several practical categories. ABSOLUTE contraindications are situations where the drug should not be used because the risk clearly outweighs any benefit; for all three incretin-based agents this includes a personal or family history of medullary thyroid carcinoma or MEN2, prior serious hypersensitivity to the drug, and generally pregnancy. RELATIVE contraindications are conditions where use may be possible but requires caution and close monitoring, such as severe gastrointestinal disease (e.g., gastroparesis), history of pancreatitis, gallbladder disease, advanced frailty, or high risk of dehydration; these concerns tend to be mildest with semaglutide, more notable with tirzepatide, and potentially greater with retatrutide because its added glucagon activity increases metabolic stress. TEMPORARY contraindications are short-term reasons to hold therapy, such as acute severe nausea/vomiting, dehydration, acute pancreatitis workup, or before major surgery where slowed gastric emptying could increase aspiration risk. PERMANENT contraindications include MEN2, medullary thyroid carcinoma, or a proven severe allergic reaction to the medication. DIRECT contraindications are problems caused by the drug’s own mechanisms, such as worsening gastroparesis, severe GI intolerance, or recurrent pancreatitis, while INDIRECT contraindications arise from downstream effects like volume depletion, electrolyte imbalance, or excessive lean mass loss if nutrition is poor. DISEASE-DRUG contraindications include conditions like severe gastroparesis, certain endocrine tumor syndromes, or unstable pancreatitis history, and procedural contraindications mainly involve holding these agents before anesthesia or endoscopy due to delayed gastric emptying. So, semaglutideis usually the most conservative and predictable option, tirzepatide offers greater metabolic effect with similar but sometimes stronger GI risks, and retatrutide is the most potent and potentially most stressful metabolically, so it demands the greatest caution, slow titration, and careful patient selection. If you are not sure where you are in the scheme of your own therapy, consult your PCP to go over potential contraindications before you start your RS journey. The more you know.
0
0 comments
GLP-1 RA Categories of Contraindications: Brief
skool.com/kristinas-peptide-junkies-24-4251
Advance your peptide research with precise, science-driven guidance, expert community talk, and access to vetted suppliers, promotions, and giveaways.
Leaderboard (30-day)
1
+7
2
+5
3
+4
4
+3
5
+3
Powered by